These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322 [TBL] [Abstract][Full Text] [Related]
45. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Kastl L; Brown I; Schofield AC Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894 [TBL] [Abstract][Full Text] [Related]
46. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575 [TBL] [Abstract][Full Text] [Related]
47. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Kai Y; Peng W; Ling W; Jiebing H; Zhuan B Biochem Biophys Res Commun; 2014 Jun; 448(3):308-14. PubMed ID: 24530397 [TBL] [Abstract][Full Text] [Related]
48. Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Jin YY; Chen QJ; Xu K; Ren HT; Bao X; Ma YN; Wei Y; Ma HB Mol Cell Biochem; 2016 Nov; 422(1-2):161-170. PubMed ID: 27644195 [TBL] [Abstract][Full Text] [Related]
49. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Yu ZW; Zhong LP; Ji T; Zhang P; Chen WT; Zhang CP Oral Oncol; 2010 Apr; 46(4):317-22. PubMed ID: 20219416 [TBL] [Abstract][Full Text] [Related]
50. miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. Long QZ; Du YF; Liu XG; Li X; He DL Tumour Biol; 2015 Sep; 36(9):7017-26. PubMed ID: 25861751 [TBL] [Abstract][Full Text] [Related]
51. Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages. Komohara Y; Ma C; Yano H; Pan C; Horlad H; Saito Y; Ohnishi K; Fujiwara Y; Okuno Y; Nosaka K; Shimosaki S; Morishita K; Matsuoka M; Wakayama T; Takeya M J Clin Exp Hematop; 2017 Jul; 57(1):15-20. PubMed ID: 28420814 [TBL] [Abstract][Full Text] [Related]
52. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence. Wu N; Jia D; Bates B; Basom R; Eberhart CG; MacPherson D J Clin Invest; 2017 Mar; 127(3):888-898. PubMed ID: 28165337 [TBL] [Abstract][Full Text] [Related]
53. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]
54. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856 [TBL] [Abstract][Full Text] [Related]
55. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633 [TBL] [Abstract][Full Text] [Related]
56. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366 [TBL] [Abstract][Full Text] [Related]
57. miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Xu K; Chen G; Qiu Y; Yuan Z; Li H; Yuan X; Sun J; Xu J; Liang X; Yin P Oncotarget; 2017 Mar; 8(13):21719-21732. PubMed ID: 28423513 [TBL] [Abstract][Full Text] [Related]
58. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. Beckers A; Van Peer G; Carter DR; Gartlgruber M; Herrmann C; Agarwal S; Helsmoortel HH; Althoff K; Molenaar JJ; Cheung BB; Schulte JH; Benoit Y; Shohet JM; Westermann F; Marshall GM; Vandesompele J; De Preter K; Speleman F Cancer Lett; 2015 Sep; 366(1):123-32. PubMed ID: 26123663 [TBL] [Abstract][Full Text] [Related]
59. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037 [TBL] [Abstract][Full Text] [Related]
60. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Lee KH; Lin FC; Hsu TI; Lin JT; Guo JH; Tsai CH; Lee YC; Lee YC; Chen CL; Hsiao M; Lu PJ Biochim Biophys Acta; 2014 Sep; 1843(9):2055-66. PubMed ID: 24915000 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]